Nymox Reports Positive Results For NX-1207

Nymox Pharmaceuticals (Nymox) has reported positive and repeatable results for NX-1207 in laboratory studies of human prostate cancer.

In addition, local injection of NX-1207 has showed activity in animals with transplanted human prostate carcinoma. The NX-1207 used in these studies is a different formulation and a much higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH).

Reportedly, NX-1207 has been tested in humans since 2003 for benign prostatic hyperplasia (BPH), and has been shown safety profile, with no known serious drug side effects seen in studies to date. The laboratory studies of prostate cancer were conducted over a 2-year period, using human prostate cancer cell lines and numerous different standard well-established methods.

The company said that NX-1207 is in phase III development for the treatment of BPH. The drug has been successful in a series of blinded controlled multi-center US clinical trials, where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. The company plans to advance NX-1207 into human clinical trials for the focal treatment of localised prostate cancer.

Moreover, the company claims that NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort. Patients notice improvement as early as a week or two after treatment. Follow-up studies have shown that many men showed continued benefit from a single NX-1207 treatment for 2 years or more. NX-1207 treatment does not require the patient to take pills daily for the rest of his life, like currently approved BPH medications, and does not have the side effects associated with approved drugs which can include sexual dysfunction, dizziness and other adverse reactions.